May 2026
📣 VC round data is live. Check it out!
Largest Nutraceuticals & Cosmeceuticals Public Companies in Sweden
Benchmark revenue and EBITDA valuation multiples for public comps like
BioGaia, Enzymatica, Simris Group and Enorama Pharma.
 | BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas. | $14 | +32% | $1B | $1B | 7.7x | 27.2x | ||
| Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period. | $0 | -21% | $62M | $59M | 9.9x | (11.9x) | ||
| Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand. | $0 | +3% | $12M | $12M | 69.7x | (7.8x) | ||
| Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform. | $0 | -84% | $3M | $3M | 8.7x | (0.3x) | ||
| Median | $0 | -9% | $37M | $36M | 9.3x | (4.1x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.